K Lesniakowski studies ulcerative colitis, which is a chronic condition affecting the intestines, causing inflammation and ulceration. Their main research effort centers on the use of propionyl-L-carnitine, a supplement that may enhance symptom relief for patients who are already receiving stable treatments. The goal of this research is to discover better management strategies for individuals suffering from this condition, potentially leading to improved quality of life.
Key findings
72% of patients taking propionyl-L-carnitine experienced a positive response to treatment, compared to 50% in the placebo group.
Propionyl-L-carnitine therapy demonstrated a significant improvement in symptoms for ulcerative colitis patients already on stable medication.
The treatment was generally safe, with side effects primarily involving the gastrointestinal tract.
Frequently asked questions
Does Dr. Lesniakowski study ulcerative colitis?
Yes, Dr. Lesniakowski specializes in research related to ulcerative colitis and explores new treatment options for the condition.
What treatments has Dr. Lesniakowski researched?
Dr. Lesniakowski has researched propionyl-L-carnitine therapy in patients with ulcerative colitis to improve their symptoms.
Is Dr. Lesniakowski's work relevant to patients with inflammatory bowel disease?
Yes, Dr. Lesniakowski's research directly benefits patients with inflammatory bowel diseases like ulcerative colitis.
Publications in plain English
Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative Colitis Including Intestinal Ultrasound Assessment: A Multicenter, Real-World Observational Study.
2025
Journal of clinical medicine
Kaniewska M, Lewandowski K, Krogulecki M, Filipiuk A, Gonciarz M +23 more
Plain English This study looked at the effectiveness of a new medication called Upadacitinib (UPA) for treating moderate-to-severe ulcerative colitis (UC) in 76 patients. After 8 weeks, 93.4% of patients saw an improvement in their symptoms, 72.4% showed better results in their endoscopies, and 57.9% were free from symptoms completely. These findings matter because they demonstrate that UPA is not only effective but also safe for a wide range of patients with UC, providing vital assessment tools for doctors to track progress.
Who this helps: This helps patients with moderate-to-severe ulcerative colitis and their doctors.
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
2022
Journal of Crohn's & colitis
Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L +23 more
Plain English This study tested a new 4 mg budesonide suppository against a 2 mg budesonide foam to see which worked better for treating mild to moderate ulcerative proctitis. They found that both treatments were effective, with a significant number of patients achieving clinical remission and mucosal healing—specifically, the suppository matched the foam in effectiveness. Additionally, more patients preferred the suppository, highlighting its acceptability.
Who this helps: Patients with ulcerative proctitis will benefit from having effective treatment options.
High Primary Antibiotic Resistance ofStrains Isolated from Pediatric and Adult Patients in Poland during 2016-2018.
2020
Antibiotics (Basel, Switzerland)
Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K +4 more
Plain English The study examined antibiotic resistance in bacteria from 334 Polish patients (126 children and 208 adults) who had primary infections between 2016 and 2018. It found that more than half of the bacterial strains were resistant to clarithromycin (54.5% in children and 30.6% in adults) and nearly a third were resistant to metronidazole (31.8% in children and 46.9% in adults). This information is crucial because it highlights the need for monitoring antibiotic effectiveness to ensure proper treatment.
Who this helps: Patients with infections requiring antibiotic treatment.
Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
2011
Alimentary pharmacology & therapeutics
Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG +15 more
Plain English In this study, researchers looked at the effects of propionyl-L-carnitine (PLC) on patients with mild-to-moderate ulcerative colitis (UC) who were already stable on treatment. They found that 72% of patients taking PLC had a positive response to treatment, compared to 50% in the placebo group, showing that PLC may help improve symptoms. The treatment was generally safe, with side effects mostly related to the stomach.
Who this helps: This helps patients with ulcerative colitis looking for better management options.